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ABSTRACT
Silibinin is the major active constituent of silymarin, an extract of milk thistle 
seeds. Silibinin has been shown to have significant anti-cancer effects in a variety of 
malignancies. However, the molecular mechanisms of silibinin action in bladder cancer 
have not been studied extensively. In the present study, we found that silibinin (10 
μM) significantly suppressed proliferation, migration, invasion and induced apoptosis 
of T24 and UM-UC-3 human bladder cancer cells. Silibinin down-regulated the actin 
cytoskeleton and phosphatidylinositide 3-kinase (PI3K)/Akt signaling pathways in 
these cancer cell lines. These pathways were found to crosstalk through RAS cascades. 
We found that silibinin suppressed levels of trimethylated histone H3 lysine 4 and 
acetylated H3 at the KRAS promoter. Furthermore, silibinin targets long non-coding 
RNA: HOTAIR and ZFAS1, which are known to play roles as oncogenic factors in 
various cancers. This study shows that silibinin exerts anti-cancer effects through 
down-regulation of actin cytoskeleton and PI3K/Akt pathways and thus suppresses 
bladder cancer growth and progression.
INTRODUCTION
Silibinin is a polyphenolic flavonolignan and is a 
major active component in silymarin, an extract of milk 
thistle (Silybum marianum) seeds. Silibinin has been 
shown to have significant anti-cancer effects in a variety 
of cancer types [1], including prostate [1–3], bladder [4, 
5], kidney [6, 7], skin [8, 9], pancreas [10], breast [3, 11], 
lung [12–14] and colon [15, 16] cancers. Silibinin is also 
effective in inhibiting brain metastases from non-small 
cell lung cancer [17].
Bladder cancer is the 5th most common cancer 
worldwide with the lowest incidence rates in Asia and 
the highest rates in Western Europe and North America 
[18]. In the United States, bladder cancer is the 4th and 
9th most common cancer in men and women respectively, 
comprising 7% of all cancer cases in 2014. More than 
50,000 men and 16,000 women are newly diagnosed with 
bladder cancer in the United States in 2014 [19].
Several studies have revealed that proteins which 
link migratory signals to the actin cytoskeleton are 
upregulated in invasive and metastatic cancer cells [20]. 
Gain-of-function mutations in RAS genes are known to be 
the first specific genetic alterations identified in human 
cancers. The RAS proteins have been characterized as 
essential components of signaling networks controlling 
cellular proliferation, differentiation, or survival in 
association with a variety of cancers [21]. In bladder 
cancers, 77% of the analyzed bladder tumors expressed 
higher RAS levels than the surrounding normal tissues 
[22]. The phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway involved in the malignant transformation of 
human tumors and their subsequent growth, proliferation, 
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and metastasis. Given that PI3K/Akt signaling occupies 
a major place in the etiology of bladder cancers, PI3K 
inhibitors have potential to be used for the treatment of 
bladder cancers [23].
Long non-coding RNAs (lncRNAs) are a class of 
non-coding RNAs longer than 200 nucleotides. LncRNAs 
have been identified as playing critical roles in cancer. 
For instance, the lncRNA HOX transcript antisense RNA 
(HOTAIR) has been shown to facilitate tumor initiation 
and progression in various cancers, such as breast, gastric, 
colorectal, cervical, and bladder cancers [24–27]. Another 
lncRNA Zinc finger antisense 1 (ZFAS1) is reported to 
promote cancer progression in some cancers [25, 28].
This study is the first to determine the effects of a 
low concentration (10 μM) of silibinin on human bladder 
cancer cells. We identified the actin cytoskeleton and 
PI3K/Akt pathways as silibinin-induced down-regulated 
pathways, which are inter-connected through RAS. 
We further evaluated the effects of silibinin on histone 
modifications and lncRNA expression. Our results 
contribute to understanding the mechanisms underlying 
the anti-cancer effect of silibinin in bladder cancer cells.
RESULTS
Silibinin inhibits cell proliferation and induces 
apoptosis
To study the effect of silibinin on the growth of 
bladder cancer cells, T24 and UM-UC-3 cells were treated 
with 5, 10 and 25 μM silibinin. Cell proliferation assay 
showed that silibinin inhibited T24 cell proliferation 
by 20% (5 μM), 69% (10 μM) and 93% (25 μM) at 48 
hours (Figure 1A). Silibinin also inhibited UM-UC-3 
cell proliferation by 39% (5 μM), 69% (10 μM) and 77% 
(25 μM) at 48 hours (Figure 1B). These results show that 
silibinin significantly suppresses the proliferation of these 
bladder cancer cell lines in a dose-dependent manner. 
We next studied the effects of silibinin on apoptosis in 
T24 and UM-UC-3 cells using Annexin-V-FITC/PI 
labeling. Silibinin (10 μM) increased apoptosis in both 
T24 and UM-UC-3 cells (Figure 1C, 1D). These results 
indicate that silibinin suppresses T24 and UM-UC-3 cell 
proliferation and increases apoptosis.
Silibinin inhibits cell migration and invasion
T24 and UM-UC-3 cells were treated with 10 μM 
silibinin and subjected to Transwell migration assay 
without Matrigel. Silibinin reduced migration of T24 and 
UM-UC-3 cells to 16% and 58% of controls, respectively 
(Figure 2A, 2B). In addition, T24 and UM-UC-3 cells were 
treated with 10 μM silibinin and subjected to Transwell 
invasion assay with Matrigel. Silibinin reduced invasion 
of T24 and UM-UC-3 cells to 43% and 42% of controls, 
respectively (Figure 2C, 2D). Wound-healing assay also 
showed that silibinin (10 μM) reduced the migration of 
T24 and UM-UC-3 cells to 66% and 13% of controls at 48 
hours, respectively (Figure 2E, 2F). Our results show that 
silibinin (10 μM) effectively inhibits cell migration and 
invasion in bladder cancer cells.
Silibinin down-regulates RAS, PI3K/Akt and 
actin cytoskeleton pathways
Western blot analysis showed that silibinin 
suppressed RAS and related-proteins such as epidermal 
growth factor receptor (EGFR) and Son of sevenless 
homolog 1 (SOS1) (Figure 3A). In response to EGF, SOS1 
interacts with activated EGFR, through the adaptor protein, 
leading to the activation of RAS through the juxtaposition 
of SOS1 and RAS at the membrane [29, 30]. Western blot 
data also showed that silibinin decreased the expression 
of PI3K subunits such as p110 α and p85 (Figure 3A), 
which regulate Akt activation and Rac signals leading to 
actin cytoskeleton pathways. Consistently, silibinin also 
reduced Akt phosphorylation at Ser-473, Rac levels and 
the downstream signaling element of Rac (Figure 3A). 
Silibinin also down-regulated actin cytoskeleton pathway-
related proteins such as Rac, PAK1, and discoid in domain 
receptor 1 (DDR1) (Figure 3B). Related to the actin-
cytoskeleton, MMP activity is known to participate in 
actin cytoskeletal reorganization in various cell types [31]. 
In support of this, we confirmed that the MMP inhibitor 
marimastat, reduced invasion of T24 and UM-UC-3 cells 
to 66% and 68% of controls, respectively (Figure 3C, 3D).
KRAS mediates silibinin functions
To examine if the effects of silibinin on cell 
proliferation and invasion are mediated by KRAS, T24 
and UM-UC-3 cells were transfected with human KRAS 
and treated with 10 μM silibinin. Western blot analysis 
confirmed that KRAS transfection increased KRAS 
expression in silibinin-treated cells (Figure 4A). Cell 
proliferation assays showed that KRAS restored cell 
viability (Figure 4B), which was suppressed by silibinin 
(Figure 1A, 1B). Invasion assays showed that KRAS 
promoted invasion of silibinin-treated T24 and UN-UC-3 
cells (Figure 4C), which was attenuated by silibinin 
(Figure 2C, 2D).
Silibinin down-regulates KRAS mRNA 
expression and suppresses histone H3 lysine 
4 (H3K4) trimethylation (H3K4me3) and H3 
acetylation (AcH3)
Expression levels of KRAS mRNA were 
significantly down regulated in T24 and UM-UC-3 cells 
after treatment with silibinin (10 μM) compared with 
vehicle-treated control cells (Figure 5A). To determine 
whether KRAS mRNA down-regulation by silibinin is 
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linked to histone H3K4me3 at the KRAS gene promoter, 
we performed chromatin immunoprecipitation (ChIP)-
quantitative real-time PCR (qPCR) assay using T24 
and UM-UC-3 cells. ChIP-qPCR assays revealed 
that histone H3K4me3 was recruited to the ChIP-4 
region of the KRAS gene promoter (Figure 5B, 5C). 
We further demonstrated that recruitment of histone 
H3K4me3 to the KRAS promoter ChIP-4 region was 
attenuated by silibinin treatment (Figure 5D). Similar 
results were obtained with AcH3 (Figure 5C, 5D). 
Given that methylation at lysine 4 of H3K4 and H3 
hyperacetylation are associated with active transcription 
[19], these results indicate that silibinin suppressed the 
recruitments of histone H3K4me3 and AcH3 to the 
KRAS promoter, which results in repression of KRAS 
gene transcription.
Silibinin regulates expression of long non-coding 
RNA
To study the effect of silibinin on lncRNAs 
which have been shown to regulate bladder cancer, 
we treated bladder cancer cell lines with silibinin and 
assayed levels of tumor-related lncRNAs. Silibinin was 
found to significantly decrease the expression levels 
of oncogenic HOTAIR and ZFAS1 (Figure 6A, 6B). 
Silibinin (10 μM) had no significant effects on the levels 
of other lncRNAs such as metastasis-associated lung 
adenocarcinoma transcript 1 (MALAT1), maternally 
expressed 3 (MEG3), and growth arrest specific 5 
(GAS5) (Supplementary Figure 1). These data indicate 
that silibinin exerts its effects via modulating oncogenic 
lncRNAs expression. As described above, silibinin may 
exert its anti-cancer effects by down-regulating RAS-
driven actin cytoskeleton and PI3K/Akt pathways. 
PI3K is considered one of the main effector pathways of 
RAS. Thus, we investigated the relationship between the 
PI3K pathway and lncRNAs using the PI3K inhibitor, 
wortmannin. Wortmannin significantly decreased the 
expression level of HOTAIR in UM-UC-3 cells and 
showed a similar tendency in T24 cells (Supplementary 
Figure 2A). However, wortmannin had no effect on 
ZFAS1 expression in both UM-UC-3 and T24 cells 
(Supplementary Figure 2B).
DISCUSSION
We found that silibinin (10 μM), at lower 
concentrations than previously reported (50–100 μM) [4, 
5, 32], inhibits cell growth, cell migration, cell invasion, 
and induces apoptosis in human bladder cancer cell lines. 
Silibinin down-regulates expression of genes in the actin 
Figure 1: Silibinin inhibits proliferation and induces apoptosis in bladder cancer cells. T24 (A) and UM-UC-3 (B) bladder 
cancer cells were seeded at a density of 3.78×104 cells per well in 6-well plates. Silibinin at the indicated concentration (5, 10, or 25 μM) 
was added and cell viability was measured by cell proliferation assay at 48 hours. T24 (C) and UM-UC-3 (D) cells were incubated for 2 
days and the cells were stained with AnnexinV-FITC/PI and apoptosis was analyzed by flow cytometry. One–way ANOVA followed by 
Dunnett's post hoc test (A, B). Two-tailed Student's t-test (C, D). Percentages in control-treated cells were defined as 100% (A, B). *p < 
0.05, **p < 0.01, ***p < 0.001.
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Figure 2: Silibinin inhibits cell migration and invasion in bladder cancer cells. T24 and UM-UC-3 cells were initially incubated 
with silibinin (10 μM) for 48 hours for migration assays and 72 hours for invasion assays. The cells were then harvested and subjected to 
migration assays for 24 hours (A, B) or invasion assays for 48 hours (C, D). T24 (E) and UM-UC-3 (F) cells were incubated with silibinin 
(10 μM) for 48 hours and wound healing assays were performed. Two-tailed Student's t-test (A-F). Percentages in control-treated cells were 
defined as 100% (A-F). *p < 0.05, **p < 0.01, ***p < 0.001.
cytoskeleton and PI3K/Akt pathways. We also show that 
silibinin suppressed RAS expression, which is regulated 
by histone modification (H3K4me3 and AcH3). Moreover, 
silibinin suppressed the expression of lncRNA HOTAIR 
and ZFAS1, which are reported to promote several types 
of cancers.
The cytoskeleton maintains the shape and internal 
organization of cells, and also functions in cell division 
and migration. Cell migration is initiated by an actin-
dependent protrusion of the cell’s leading edge, which is 
composed of structures called lamellipodia and filopodia. 
Therefore, actin and the cytoskeleton are fundamental 
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for cell migration, a critical step in cancer invasion 
and metastasis. Rac-PAK1 signaling, down-regulated 
by silibinin (Figure 3B), is known to be critical for the 
cytoskeleton [33]. In addition, there is evidence for 
the importance of the RAS-driven Rac–PAK1 effector 
signaling pathway in cancer development and growth [33]. 
DDR1 which was reduced by silibinin (Figure 3B) triggers 
epithelial cell differentiation by promoting cell adhesion 
[34]. Given the literature and our finding that silibinin 
significantly down-regulates actin cytoskeleton-related 
Ras-Rac-PAK1 pathways (Figure 3A, 3B), the inhibitory 
effects of silibinin on cell migration in vitro might be 
explained by reduced cytoskeleton organization and/or 
dynamics. This is supported by studies on the relationship 
between MMPs and actin cytoskeletal reorganization 
[31] and our results from invasion assay using the MMP 
inhibitor marimastat.
PI3K signaling promotes cellular transformation 
and cancer development, and controls the actin-
cytoskeleton pathway [35] through regulating RAS 
[36]. PI3K is one of the main effector pathways of RAS, 
regulating cell growth, cell survival, and cytoskeleton 
Figure 3: Silibinin down-regulates expression of genes in PI3K/Akt signaling and actin cytoskeleton pathways. 
Expression of genes in PI3K/Akt signaling pathway (A) and actin cytoskeleton pathways (B) were assayed by Western blot following 10 
μM silibinin treatment for 72 hours. T24 (C) and UM-UC-3 (D) cells were incubated with marimastat (1 μM) for 48 hours and the cells were 
harvested and subjected to Transwell invasion assay with Matrigel. EGFR: Epidermal Growth Factor Receptor; SOS1: Son of Sevenless 
Homolog 1, Rac: Ras-Related C3 Botulinum Toxin Substrate, PAK1: P21 Protein (Cdc42/Rac)-Activated Kinase 1, DDR1 (RTK): Receptor 
tyrosine kinases. Two-tailed Student's t-test (C, D). Percentages in control-treated cells were defined as 100% (C, D). *p < 0.05, **p < 0.01.
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Figure 4: KRAS restores cell proliferation which is suppressed by silibinin. T24 and UM-UC-3 cells were treated with 10 μM 
silibinin after transfection with vector only or vector expressing KRAS for 48 hours. KRAS expression was analyzed by Western blot (A). 
Cell viability (B) and cell invasion (C) were evaluated at 48 hours after treatment with 10 μM silibinin. Two-tailed Student's t-test (B, C). 
Percentages in control-treated cells were defined as 100% (B, C). * p < 0.05.
Figure 5: Silibinin suppressed histone H3 lysine 4 (H3K4) trimethylation (H3K4me3) and H3 acetylation (AcH3) and 
down-regulated KRAS expression. (A) Relative KRAS mRNA expression after 10 μM silibinin treatment for 48 hours. (B) Schematic 
representation of the promoter region of the human KRAS gene and primer set location. (C) ChIP assays were performed to detect Ras 
levels at multiple primer sets (ChIP 1-ChIP 6). (D) The relative enrichment of H3K4me3 and AcH3 at ras primer-4 (ChIP-4) decreased 
after silibinin treatment for 48 hours. Two-tailed Student's t-test (A). Expression levels in control-treated cells were defined as 1 (A). *p < 
0.05, ***p < 0.001.
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reorganization [37]. Rac is also a key downstream 
effector of PI3K [38]. Thus, our Western blotting data 
showing that silibinin down-regulates both RAS and 
PI3K/Akt is consistent with these findings. The actin 
cytoskeleton pathway was also reported to crosstalk 
through PI3K in an AKT-independent manner [39]. In 
the presence of silibinin, KRAS overexpression restored 
cell proliferation and invasion which were suppressed 
by silibinin in bladder cancer cells (Figure 4B, 4C). 
These results support the idea that suppressed cell 
proliferation and invasion by silibinin are mediated by 
KRAS. Our ChIP data shows that histone modifications 
regulate KRAS gene expression. Histone H3K4me3 and 
AcH3 were enriched at the KRAS promoter, and silibinin 
suppressed the enrichment of histone H3K4me3 and 
AcH3 at the KRAS promoter.
Recently, accumulating studies have demonstrated 
that lncRNAs are associated with the development of 
various types of cancers [40]. HOTAIR has been found 
to be highly expressed in several cancers and related to 
the recurrence of bladder cancer [27]. KRAS upregulates 
HOTAIR [41] and is regulated by the PI3K pathway [42]. 
This is strongly supported by our results showing that PI3K 
inhibitor wortmannin downregulated HOTAIR expression 
in human bladder cancer cells (Supplementary Figure 2A). 
These findings are consistent with our findings showing 
that silibinin down-regulated the PI3K pathway (Figure 
3A), KRAS (Figure 5A) and HOTAIR (Figure 6A).
In summary, this study shows that 10 μM silibinin 
induces apoptosis and inhibits cell growth, migration 
and invasion in human bladder cancer cells. Silibinin 
significantly down-regulates the RAS-driven actin 
cytoskeleton and PI3K/Akt pathways. Our data shows that 
silibinin down-regulates KRAS by suppressing histone 
H3K4 and AcH3 enrichment at the KRAS promoter. 
Furthermore, silibinin may exert its anti-cancer effects 
by suppressing oncogenic lncRNAs such as HOTAIR 
and ZFAS1. Hence, these pathways down-regulated by 
silibinin cooperatively exert tumor suppressing effects 
in bladder cancer cells. Currently, only a minority of 
patients with advanced bladder cancer are cured following 
treatment with standard therapies. This study may thus 
be important for development of silibinin as a drug for 
bladder cancer treatment.
Figure 6: Silibinin down-regulates expression of oncogenic lncRNAs: HOTAIR and ZFAS1. Expression of long non-coding 
RNA HOTAIR (A) and ZFAS1 (B) after treatment of T24 and UM-UC-3 cells with silibinin (10 μM) for 4 hours as determined by real-
time PCR (mean ± SD). GAPDH was used as an internal control. Data were obtained from three independent experiments performed in 
triplicate. Two-tailed Student's t-test (A, B). Expression levels in control-treated cells were defined as 1 (A, B). *p < 0.05, ***p < 0.001.
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MATERIALS AND METHODS
Regents
Silibinin, marimastat, and wortmannin were 
purchased from Sigma–Aldrich (St. Louis, MO, 
USA). RIPA buffer was purchased from Cell Signaling 
Technology (Boston, MA, USA), protease inhibitor 
and phosphatase inhibitor were from Roche (Basel, 
Switzerland). BCA qualification system was purchased 
from Pierce (Rockford, IL, USA). The following 
antibodies were purchased from Cell Signaling Technology 
(Danvers, MA): PI3 Kinase p110α (4249), PI3 Kinase 
p85 (4257), Akt (4691), phospho-Akt (Ser473) (Ser473) 
(4060), Ras (3339), SOS1 (12409), PAK1 (2602), Rac 
1/2/3 (2465), DDR1 (RTK6) (5583) and GAPDH (97166).
Cell culture
Human bladder carcinoma cell lines, T24 and UM-
UC-3 were purchased from The American Type Culture 
Collection (Manassas, VA). T24 cells were cultured in 
McCoy's 5A medium and UM-UC-3 cells were cultured 
in Eagle's Minimum Essential medium. Both were 
supplemented with 10% fetal bovine serum (FBS) and 
1% penicillin-streptomycin in a humidified atmosphere 
of 5% CO2 and 95% air at 37°C. Silibinin, marimastat, 
and wortmannin were dissolved in dimethyl sulfoxide 
(DMSO). The final concentration of DMSO in the culture 
did not exceed 0.1% (v/v).
Transfection
KRAS expression vector was purchased from 
Origene (Rockville, MD). Transfection was performed 
using X-tremeGENE HP DNA Transfection Reagent 
(Roche) according to the manufacturer’s protocols.
Cell proliferation assay
Cells (T24 and UM-UC-3) were seeded at a 
density of 3.78 ×104 cells per well in 6-well plates. After 
48 hours treatment with silibinin, cell proliferation/
viability was assessed by counting cell numbers with 
a microscope or by using CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay (Promega, Madison, 
WI), a colorimetric assay which measures the activity of 
reductase enzymes. At the indicated times, CellTiter 96 
Aqueous One reagent was added to each well according 
to the manufacturer's instructions. Cell viability was 
determined by measuring the absorbance at 490 nm using 
a kinetic microplate reader (Spectra MAX 190; Molecular 
Devices Co., Sunnyvale, CA). Data are the mean ± 
standard deviation (SD) of three independent experiments.
Apoptosis analysis
Cells (T24 and UM-UC-3) were seeded at a density 
of 1×106 cells per well in 6-well plates. After 48 hours 
treatment with silibinin, apoptotic cells were measured 
using flow cytometry (Cell Lab Quanta SC, Beckman 
Coulter, Brea, CA) with Annexin-V-FITC/PI labeling 
(BD Pharmingen, San Diego, CA). Measurements were 
repeated independently three times.
Transwell invasion/migration assay
T24 and UM-UC-3 cells were grown in Dulbecco's 
Modified Eagle's Medium (DMEM) containing 10% 
FBS. For invasion assay, culture inserts of 8-μm pore 
size (Transwell; Corning Costar, Corning, NY) were 
coated with Matrigel (BD Biosciences, San Jose; 100 
μg per well). For migration assay, no Matrigel was 
used. Inserts were placed into the wells of 24-well 
culture plates. In the lower chamber, 500 μl of DMEM 
containing 10% FBS was added. The cells which were 
pretreated with silibinin (10 μM) for 48 hours for 
migration assay and for 72 hours for invasion assay 
were seeded to the upper chamber. After incubation for 
24 hours for migration assay and 48 hours for invasion 
assay at 37°C with 5% CO2, the cells that had migrated 
through the pores were fixed with 10% formaldehyde 
and stained with 0.05% Crystal Violet. Crystal Violet 
was solubilized with methanol and absorbance (540 nm) 
of the solution was measured by a kinetic microplate 
reader (Spectra MAX 190; Molecular Devices Co., 
Sunnyvale, CA). Data are the mean ± S.D. of three 
independent experiments.
Wound-healing assay
T24 (3×105) and UM-UC-3 (7×105) cells were 
seeded in 6-well plates and treated with silibinin (10 
μM) for 48 hours. A wound was formed by scraping the 
cells with a 200-μl pipette tip and was washed twice with 
medium. Cells were observed and photographed with a 
microscope at various times after scraping.
Western blot analysis
Protein extracts were resolved by sodium dodecyl-
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and transferred to polyvinylidene fluoride membranes 
(Hybond-P; GE Healthcare, Piscataway, NJ), followed 
by incubation with the indicated primary and secondary 
antibodies conjugated to horseradish peroxidase (GE 
Healthcare). Signals were detected using the ECL 
detection system (Amersham ECL plus Western Blotting 
detection system, Fairfield, CT).
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ChIP assay
ChIP analysis was performed using the EZ-Magna 
ChIP kit (Millipore) according to the manufacturer's 
directions. In short, cells were incubated with 1% 
formaldehyde for 10 min at room temperature and 
quenched unreacted formaldehyde with 125 mM glycine 
for 5 min. The cells were washed twice with phosphate 
buffered saline and subjected to chromatin preparation 
according to the kit procedure. ChIP was performed 
using antibodies against Tri-methyl-histone H3K4 (9751, 
Cell Signaling), Tri-methyl-histone H3K27 (9733, Cell 
Signaling), acetyl-histoneH3 upstate (06-599, Millipore), 
RNA polymerase II antibody (05-623B, Millipore), and 
an antibody against mouse IgG (12-371B, Millipore) was 
used as a negative control. Precipitated genomic DNA 
was amplified by real-time PCR. PCR was performed 
using STBR Green PCR master mix according to the 
manufacturer’s suggestions (Qiagen, Valencia, CA, USA). 
The primer list is shown in Supplementary Table 1.
Total RNA and protein extraction
Total RNA was extracted from cultured bladder cell 
lines using miRNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Cells were lysed with RIPA 
buffer (Thermo Scientific, Pierce) containing protease and 
phosphatase inhibitor cocktail (Thermo Scientific).
Reverse transcription and real-time PCR
cDNA was synthesized using an iScript Synthesis 
Kit (Bio-Rad, Hercules, CA, USA). QPCR analysis 
was performed in triplicate with an Applied Biosystems 
Prism 7500 fast Sequence Detection System using 
Taqman universal PCR master mix fast according to the 
manufacturer’s protocol (Applied Biosystems Inc., Foster 
City, CA, USA). The Taqman probes and primers for 
HOTAIR, ZFAS1, MALAT1, MEG3, and GAS5 were 
purchased from Applied Biosystems. Human GAPDH were 
used as an internal control. PCR primers used in QPCR 
assays are listed in Supplementary Table 1. Levels of RNA 
expression were determined by using the 7500 Fast System 
SDS software version 1.3.1 (Applied Biosystems).
Statistical analysis
Data are shown as mean values ± standard deviation 
(SD) or standard error of the mean (SEM). The Student's 
t-test was used to compare the two different groups. P 
values of less than 0.05 were regarded as statistically 
significant.
Abbereviations
AcH3, H3 acetylation; DDR1, discoid in domain 
receptor 1; EGFR, epidermal growth factor receptor; 
GAS5, growth arrest specific 5; H3K4me3, histone 
H3 lysine trimethylation; HOTAIR, HOX transcript 
antisense RNA; MALAT1, metastasis-associated lung 
adenocarcinoma transcript 1; MEG3, maternally expressed 
3; PAK1, P21 Protein (Cdc42/Rac)-Activated Kinase 
1; PI3K/Akt, phosphatidylinositol 3-kinase; Rac, Ras-
Related C3 Botulinum Toxin Substrate; SOS1, Son of 
sevenless homolog 1; ZFAS1, Zinc finger antisense 1.
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